


In one embodiment, the invention provides a compound of the formula (0):



or a salt, N-oxide or tautomer thereof, wherein:

T^1 is selected from N and CH;

5 T^2 is selected from N, CH and CF;

R^1 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^2 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^3 is selected from hydrogen, methyl, fluorine, chlorine and bromine;

10 one of M^1 and M^2 is a group R^4 selected from hydrogen, methyl, fluorine, chlorine and bromine; and the other of M^1 and M^2 is a moiety $-A-R^7$;

R^5 is selected from hydrogen, cyano, C_{1-3} alkyl, cyclopropyl, chlorine, carboxy, and C_{1-3} -alkoxy-carbonyl;

15 R^6 is selected from hydrogen, fluorine, C_{1-4} alkyl; and C_{1-4} alkoxy optionally substituted with NR^dR^e where R^d and R^e are the same or different and each is selected from hydrogen and C_{1-4} alkyl, or NR^dR^e forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from N, O and S and oxidized forms of S, the saturated heterocyclic ring being optionally substituted with one or more substituents selected from oxo, methyl, hydroxy and fluorine;

A is selected from:

20 (i) a bond;

(ii) $(CR^pR^q)_x$ where R^p and R^q are each independently hydrogen or methyl and x is 1 to 4;

(iii) an oxygen atom;

(iv) a group NR^r wherein R^r is hydrogen or methyl; and

25 (v) a saturated chain of 2 to 10 chain members in length containing at least one carbon atom chain member, at least one heteroatom chain member selected from nitrogen and oxygen, and optionally one or more further carbon atom chain members and/or heteroatom chain members selected from nitrogen, oxygen, sulphur, sulphinyl and sulphonyl; the saturated chain being optionally substituted

with one or more substituents selected from =O, C₁₋₄ hydrocarbyl, fluoro-C₁₋₄ hydrocarbyl, hydroxy-C₁₋₄ hydrocarbyl, C₁₋₂-alkoxy-C₁₋₄ hydrocarbyl, and fluorine wherein two hydrocarbyl substituents on the same carbon atom may optionally link to form a ring of three to five ring members;

R⁷ is selected from hydrogen; R¹¹SO₂-; amino; NH-Hyd¹; N(Hyd¹)₂; and a group Cyc¹ wherein Cyc¹ is a carbocyclic or heterocyclic aromatic or non-aromatic group of 3 to 10 ring members of which 0 to 3 are selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic aromatic or non-aromatic group being optionally substituted with one or more substituents R⁸; provided that when A is a bond, (CR^pR^q)_x, an oxygen atom or NR^r, then R⁷ is other than hydrogen; and provided also that when R⁷ is hydrogen, then A has a chain length of at least four chain members and contains at least two heteroatom chain members;

R⁸ is selected from:

- halogen;
- oxo;
- cyano;
- nitro;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R⁹; and
- a group R^a-R^b;

R^a is a bond, O, CO, X¹C(X²), C(X²)X¹, X¹C(X²)X¹, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂;

R^b is:

- hydrogen;
- a carbocyclic and heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R⁹;
- an acyclic C₁₋₁₂ hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C₁₋₈ non-aromatic hydrocarbylamino; and carbocyclic and heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R⁹; wherein one or more but not all of the carbon atoms of the acyclic

- C₁₋₁₂ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹;

R^c is:

- hydrogen;

- a carbocyclic and heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R⁹;

- an acyclic C₁₋₁₂ hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C₁₋₈ non-aromatic hydrocarbylamino; and carbocyclic and heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R⁹; wherein one or more but not all of the carbon atoms of the acyclic C₁₋₁₂ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NH, N-C₁₋₄ alkyl, C(O)O, OC(O), NH(CO), C(O)NH, NH(CO)NH, N(C₁₋₄ alkyl)C(O), C(O)N(C₁₋₄ alkyl)

X¹ is O, S or NR^c; and

X² is =O, =S or =NR^c;

wherein R⁹ is selected from R⁸ provided that when the substituents R⁹ contain a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group is unsubstituted or substituted with one or more substituents R¹⁰;

R¹⁰ is selected from halogen, oxo, cyano, and an acyclic C₁₋₆ hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; carboxy; amino; mono- or di-C₁₋₂ alkylamino; wherein one but not all of the carbon atoms of the acyclic C₁₋₆ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NH or NMe;

R¹¹ is selected from amino, Hyd¹, NH-Hyd¹, N(Hyd¹)₂; and Cyc¹;

Hyd¹ is a non-aromatic C₁₋₆ hydrocarbyl group optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, amino and Cyc¹, wherein one or two of the carbon atoms of the non-aromatic C₁₋₆ hydrocarbyl group may optionally be replaced by O, NH, N-Hyd², C(=O), S, SO or SO₂, provided that at least one carbon atom of the hydrocarbyl group remains;

Hyd² is a C₁₋₄ hydrocarbyl group;

and wherein in any group consisting of or containing a hydrocarbyl moiety, the hydrocarbyl moiety is a hydrocarbon group optionally containing one or more single, double or triple carbon-carbon bonds or combinations thereof.

5 In one embodiment, the invention provides a combination comprising a compound as disclosed herein and another chemotherapeutic agent, for example an anticancer drug.

In one embodiment, the invention provides the use of a compound as disclosed herein, optionally in combination with another chemotherapeutic agent or radiotherapy in the manufacture of a medicament for the treatment of a proliferative disease.

15. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable excipient.

16. A combination comprising a compound as defined in claim 1 and another chemotherapeutic agent, for example an anticancer drug.

17. Use of a compound as defined in claim 1, optionally in combination with another chemotherapeutic agent or radiotherapy in the manufacture of a medicament, ~~for use in the~~ treatment of a proliferative disease.

~~18. An invention as defined in any one of Embodiments 1.0 to 1.107, 2.1 to 2.28, 3.1, 4.1 and 5.1 as defined herein.~~